Close

FRα (Folate receptor-alpha)

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Product List Background Anti-FRα CAR-T Services Anti-FRα CAR-T In Vitro Assay ServicesAnti-FRα CAR-T In Vivo Assay Services

Product List

Our team of experts has extensive experience in the design and optimization of anti-FRα CAR constructs. Please browse the list below to find the product you want. We also customize our products to meet your specific needs.

Background

Folate receptor-alpha (FRα), also known as FOLR1, FBP, FOLR, FR1, is a glycosylphosphatidyl-inositol-linked protein encoded by the FOLR1 gene. This receptor is a membrane-bound protein with a high affinity for binding and transporting physiologic levels of folate into cells. Compared to normal cells, FRα is overexpressed on ovarian and several other epithelial malignancies including renal cancer, lung cancer, and breast cancer. Therefore, FRα can be used as a target for imaging and therapy.

Associated Disease

Ovarian cancer

Renal cancer

Lung cancer

Breast cancer

Others

Anti-FRα CAR-T Services

Anti-FRα CAR-T In Vitro Assays

Anti-FRα CAR-T Expression Test

At Creative Biolabs, our CAR-T cell proliferation service not only offers innovative CAR detection reagents but also provides a comprehensive range of assay services to support your research projects. For example, flow cytometry is a common tool to evaluate Anti-FRα CAR expression at the single-cell level, providing quantitative and qualitative information.

Fig.1 Evaluation of anti-FRα CAR expression. (Song, et al., 2016)Fig.1 Evaluation of anti-FRα CAR expression. The results show primary human CD3 T cells can efficiently express FRα-specific CAR.1

Anti-FRα CAR-T Cytokine Release Test

The cytokine release test not only provides valuable insights into the safety and efficacy of the final product but also helps identify potential side effects or toxicities associated with the treatment. Our comprehensive cytokine release test services offer a comprehensive and sensitive approach for measuring these key cytokines, such as TNF-α and IFN-γ.

Fig.2 IFN-γ secretion by anti-FRα CAR-T cells co-cultured with FRα+ cancer cell lines. (Song, et al., 2011)Fig.2 IFN-γ secretion by anti-FRα CAR-T cells co-cultured with FRα+ cancer cell lines. The anti-FRα CAR-T cells secreted high levels of IFN-γ.2

Anti-FRα CAR-T In Vitro Cytotoxicity Assay

We offer cytotoxicity assay services to support the evaluation of anti-FRα CAR-T cell therapy. We utilize various cytotoxicity assays including radioactive chromium release assay, bioluminescence, and flow cytometry to test in vitro antitumor efficacy.

Fig.3 Cytolytic activity of anti-FRα CAR-T cells against FRα- C30 cell and FRα+ MDA-231 cells. (Song, et al., 2016)Fig.3 Cytolytic activity of anti-FRα CAR-T cells against FRα- C30 cell and FRα+ MDA-231 cells. anti-FRα CAR-T cells exhibited antigen-specific killing of FRα+ tumor cells.1

Anti-FRα CAR-T In Vivo Assays

Efficacy Test of Anti-FRα CAR-T

Creative Biolabs uses various tools and technologies to study the in vivo biology of anti-FRα CAR-T cells. We assess the antitumor activity of anti-FRα CAR-T cells against FRα+ cancer cells in mouse models.

Fig.4 In vivo anti-tumor activity of anti-FRα CAR-T cells. (Song, et al., 2016)Fig.4 In vivo anti-tumor activity of anti-FRα CAR-T cells. Anti-FRα CAR-T cells induce rapid tumor regression of MDA-231 in vivo.1

Toxicity Evaluation Anti-FRα CAR-T

At Creative Biolabs, we offer a comprehensive solution for the evaluation of CAR-T cell toxicity to ensure the safety and efficacy of the final product. We provide a range of in vivo toxicity study services to support your CAR-T research projects. These services include tumorigenicity study, tumor lysis analysis, on-target toxicity, and off-target toxicity.

References

  1. Song, De-Gang, et al. "Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level." Journal of hematology & oncology 9.1 (2016): 1-12.
  2. Song, De-Gang, et al. "In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)." Cancer research 71.13 (2011): 4617-4627.
  • CAR Vector Products

  • CAR Viral Particles

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-T-1-M313-2 Anti-FRα scFv h(CD28) CART, pCDCAR1 Human MOv19 Mouse scFv-CD28 Lentiviral T cell   Add to Cart   Datasheet
CAR-T-1-M313-G Anti-FRα scFv h(FcεRIγ) CART, pCDCAR1 Human MOv19 Mouse scFv-FcεRIγ Lentiviral T cell   Add to Cart   Datasheet
CAR-T-1-M313-Z Anti-FRα scFv h(CD3ζ) CART, pCDCAR1 Human MOv19 Mouse scFv-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-T-2-M313-2G Anti-FRα scFv h(CD28-FcεRIγ) CART, pCDCAR1 Human MOv19 Mouse scFv-CD28-FcεRIγ Lentiviral T cell   Add to Cart   Datasheet
CAR-T-2-M313-2Z Anti-FRα scFv h(CD28-CD3ζ) CART, pCDCAR1 Human MOv19 Mouse scFv-CD28-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-T-2-M313-4G Anti-FRα scFv h(CD4-FcεRIγ) CART, pCDCAR1 Human MOv19 Mouse scFv-CD4-FcεRIγ Lentiviral T cell   Add to Cart   Datasheet
CAR-T-2-M313-4Z Anti-FRα scFv h(CD4-CD3ζ) CART, pCDCAR1 Human MOv19 Mouse scFv-CD4-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-T-2-M313-8Z Anti-FRα scFv h(CD8-CD3ζ) CART, pCDCAR1 Human MOv19 Mouse scFv-CD8-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-T-2-M313-BZ Anti-FRα scFv h(41BB-CD3ζ) CART, pCDCAR1 Human MOv19 Mouse scFv-41BB-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-T-2-M313-CZ Anti-FRα scFv h(b2c-CD3ζ) CART, pCDCAR1 Human MOv19 Mouse scFv-b2c-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-T-3-M313-2BZ Anti-FRα scFv h(CD28-41BB-CD3ζ) CART, pCDCAR1 Human MOv19 Mouse scFv-CD28-41BB-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-T-3-M313-2XZ Anti-FRα scFv h(CD28-OX40-CD3ζ) CART, pCDCAR1 Human MOv19 Mouse scFv-CD28-OX40-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-LC006 Anti-FRA (C4) h(CD28-CD3ζ) CAR, pCDCAR1 Human C4 Human scFv-CD27-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-LC040 Anti-FRA (MOv19) h(ICOS-CD3ζ) CAR, pCDCAR1 Human MOv19 Mouse scFv-ICOS-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-LC164 Anti-FRA (C4) h(CD28-CD3ζ) CAR, pCDCAR1 Human C4 Human scFv-CD28-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-LC165 Anti-FRA (C4) h(CD3ζ) CAR, pCDCAR1 Human C4 Human scFv-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-LC360 Anti-FOLR1×MSLN (X7X218) h(CD3ζ/CD28) Dual CAR, pCDCAR1 Human X7X218 Mouse scFv(MSLN)-CD3ζ/scFv(FRA)-CD28 Lentiviral T cell   Add to Cart   Datasheet
CAR-MZ154 Anti-FRα (MOv19) h(CD3ζ) CAR, pCDCAR1 Human MOv19 Mouse scFv-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-MZ155 Anti-FRα (MOv19) h(CD137-CD3ζ) CAR, pCDCAR1 Human MOv19 Mouse scFv-CD137-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.